No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
BCTXW BRIACELL THERAPEUTICS CORP C/WTS(TO PUR COM)
- 0.219
- -0.021-8.92%
Close Jul 3 13:00 ET
- 0.200
- -0.019-8.51%
Post 13:04 ET
0Market Cap0.00P/E (TTM)
0.250High0.184Low179.84KVolume0.235Open0.240Pre Close39.01KTurnover0.00%Turnover Ratio0.00P/E (Static)0Shares3.30052wk High0.00P/B0Float Cap0.17052wk Low--Dividend TTM0Shs Float7.040Historical High--Div YieldTTM27.46%Amplitude0.170Historical Low0.216Avg Price1Lot Size
Full Hours
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
10-Q: Quarterly report
BriaCell Presents Clinical Efficacy Data at ASCO 2024
BriaCell doubles Progression-Free-Survival (PFS) and Clinical Benefit Rate vs historical results in the literatureBria-IMT PFS compares favorably to PFS of most recent treatment in 48% of Antibody-Drug Conjugate
Express News | Briacell Initiates Patient Enrollment in First-in-Human Study of Bria-Ots™ in Advanced Metastatic Breast Cancer
Express News | Briacell Announces Clinical Supply Agreement With Beigene for Bria-Ots™ First in Human Study
BriaCell Doubles Progression-Free-Survival (PFS) and Reports Clinical Benefit Data at ASCO 2024
83% intracranial objective response rate (iORR) with Bria-IMT in heavily pretreated advanced breast cancer patients with CNS metastasesMedian progression free survival (PFS) of 4.1 months in ADC resistant
Express News | Briacell Therapeutics Announces Closing of $5.0 Million Registered Direct Offering
Comments
$BRIACELL THERAPEUTICS CORP C/WTS(TO PUR COM)(BCTXW.US$
well well what do we have here?? just 4 me!
well well what do we have here?? just 4 me!
1
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg